An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.
All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.
Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug temozolomide can help improve the life expectancy of patients with newly diagnosed, resected EGFRvIII positive glioblastoma.
The duration of participation in this study may be up to 5 years. After you are screened and enrolled in the study, you will be administered temozolomide and either rindopepimut/GM-CSF or KLH until either disease progression or intolerance to the medications. If your tumor progresses while on this study, your doctor may treat you with other therapies that are not part of the study.
Inclusion Criteria-
Among other criteria, patients must meet the following conditions to be eligible for the study:
Exclusion Criteria-
Among other criteria, patients who meet the following conditions are NOT eligible for the study:
Phoenix, Arizona 85013, United States
Chicago, Illinois 60611, United States
Lansing, Michigan 48912, United States
Saginaw, Michigan 48604, United States
Minneapolis, Minnesota 55407, United States
Hackensack, New Jersey 07601, United States
Great Neck, New York 11021, United States
New York, New York 10032, United States
Durham, North Carolina 27710, United States
Allentown, Pennsylvania 18103, United States
Charleston, South Carolina 29425, United States
Madison, Wisconsin 53792, United States
South Brisbane, Queensland 4101, Australia
Porto Alegre, Rio Grande do Sul 90840-440, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
São Paulo, 01321-001, Brazil
Montreal, Quebec H2L 4M1, Canada
Shenbrooke, Quebec J1H5N4, Canada
Heidelberg, 69120, Germany
Miskolc, 3526, Hungary
Szombathely, 9700, Hungary
Thiruvananthapuram, Kerala 695 011, India
Aurangabad, Maharashtra 431001, India
Andheri-West, Mumbai 400 053, India
Jasola Viha, New Delhi 110076, India
Erandauame, Pune 411004, India
Christchurch Central, Christchurch 8011, New Zealand
LaHospitalet de Lubregat, Catalonia 08908, Spain
Franca, Girona 17007, Spain
Barcelonia, 08916, Spain
Bern, 3010, Switzerland
Tainan City - Yongkang District, 710, Taiwan
Taipei City - Neihu District, 00114, Taiwan
Bangkoknoi, Bangkok 10700, Thailand
Patumwan, Bankok 10330, Thailand
Amphoe Muang, Chiang Mai 50200, Thailand